ZolpiMist: payments to doctors
Payments that named ZolpiMist as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $73K
- Providers
- 1,458
- Transactions
- 2,951
- Average per transaction
- $25
The per-transaction average — $25 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,458 providers the average total is $50, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Neos Therapeutics, LP | $30,050 | 41.4% |
| Aytu Biopharma, Inc. | $29,443 | 40.6% |
| Validus Pharmaceuticals LLC | $10,559 | 14.6% |
| Aytu Bioscience, Inc | $2,465 | 3.4% |